A prognostic score for hormone-refractory prostate cancer: Analysis of two cancer and leukemia group B studies

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 831-837

  Vollmer, Robin T ^a,e   Kantoff, Philip W ^b   Dawson, Nancy A ^c   Vogelzang, Nicholas J ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYDROCORTISONE; MEGESTROL ACETATE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BODY WEIGHT; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMOGLOBIN DETERMINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; BODY WEIGHT; DRUG RESISTANCE, NEOPLASM; HEMOGLOBINS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 0032907691     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Vollmer, R. T., Dawson, N. A., and Vogelzang, N. J. The dynamics of prostate specific antigen in hormone refractory prostate cancer: an analysis of Cancer and Leukemia Group B study 9181 of megestrol acetate. Cancer (Phila.). 83: 1989-1994, 1998.
2. Dawson, N. A., Small, E. J., Conaway, M., Lake, D., et al. Megestrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): prostate specific antigen (PSA) response and antiandrogen withdrawal (AAWD): Cancer and Leukemia Group B (CALGB) 9181. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 15: 241, 1996.
3. Dawson, N. A., Conaway, M., Winer, E. P., Lake, D., Small, E. J., Cooper, M. R., Green, M. R., Ernstoff, M., and Vogelzang, N. J. A randomized study comparing standard versus moderately high dose megestrol acetate in advanced prostate cancer: a Cancer and Leukemia Group B study. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 14: 236, 1995.
4. Kantoff, P. W., Conaway, M., Winer, E., Picus, J., and Vogelzang, N. J. Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: preliminary results from a prospective randomized Cancer and Leukemia Group B study (9182) comparing chemotherapy to best supportive care. J. Clin. Oncol., 14: 1748, 1996.
5. Cox, D. R., and Oakes, D. Analysis of survival data. London: Chapman and Hall, 1984.
6. S-PLUS Guide to Statistical and Mathematical Analysis, pp. 20.24-20.28. Seattle: StatSci Division of MathSoft, Inc., 1995.
7. Andersen, P. K., Borgan, O., Gill, R. D., and Keiding, N. Statistical Models Based on Counting Processes. New York: Springer-Verlag, 1993.
8. Venables, W. N., and Ripley, B. D. Modern Applied Statistics with S-Plus, pp 287-298. New York: Springer-Verlag, 1994.
9. Vollmer, R. T. Multivariate statistical analysis for anatomic pathology. Part II: Failure time analysis. Am. J. Clin. Pathol., 106: 522-534, 1996.
10. McCullagh, P., and Nelder, J. A. Generalized Linear Models, Ed. 2. London: Chapman and Hall, 1989.
11. Scher, H. I., Curley, T., Geller, N., Engstrom, C., Dershaw, D. D., Lin S-Y., Fitzpatrick, K., Nisselbaum, J., Schwartz, M., Berzirdjian, L., and Eisenberger M. Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease. J. Clin. Oncol., 8: 1830-1838, 1990.
12. Sridhara, R., Eisenberger, M. A., Sinibaldi, V. J., Reyno, L. M., and Egorin, M. J. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J. Clin. Oncol., 13: 2944-2953, 1995.
13. Eisenberger, M. A., and Nelson, W. G. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution. J. Natl. Cancer Inst. (Bethesda), 88: 779-781, 1996.
14. Thalmann, G. N., Sikes, R. A., Chang, S-M., Johnston, D. A., von Eschenbach, A. C., and Chung, L. W. K. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J. Natl. Cancer Inst. (Bethesda), 88: 794-801, 1996.
15. Scher, H. I., Mazumdar, M., and Kelly, W. K. Clinical trials in relapsed prostate cancer: defining the target. J. Natl. Cancer Inst. (Bethesda), 22: 1623-1634, 1996.
16. Seckin, B., Anthony, T., Murphy, B., and Steiner, M. S. Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? World J. Urol., 14: S26-S29, 1996.
17. Smith, D. C., Dunn, R. L., Strawderman, M. S., and Pienta, K. J. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J. Clin. Oncol., 16: 1835-1843, 1998.
18. Berry, W. R., Laszlo, J., Cox, E., Walker, A., and Paulson, D. Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer (Phila.), 44: 763-775, 1979.
19. Manni, A., Bartholomew, M., Caplan, R., Boucher, A., Santen, R., Lipton, A., Harvey, H., Simmonds, M., White-Hershey, D., Gordon, R., Rohner, T., Drago, J., Wettlaufer, J., and Glode, L. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J. Clin. Oncol., 6: 1456-1466, 1988.
20. Mulders, P. F. A., Dijkman, G. A., Fernandez del Moral, P., Theeuwes, A. G. M., and Debruyne, F. M. J. Analysis of prognostic factors in disseminated prostatic cancer. Cancer (Phila.), 65: 2758-2761, 1990.
21. Newling, D. W. W., Denis, L., and Vermeylen, K. Orchiectorny versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer (Phila.), 72: 3793-3798, 1993.
22. Ribeiro, M., Ruff, P., and Falkson, G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am. J. Clin. Oncol., 20: 605-608, 1997.
23. Eisenberger, M. A., Crawford, E. D., Wolf, M., Blumenstein, B., McLeod, D. G., Benson, R., Dorr, F. A., Benson, M., and Spaulding, J. T. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). Semin. Oncol., 21: 613-619, 1994.
24. Newling, D., Fossa, S. D., Andersson, L., Abrahamsson P-A., Aso, Y., Eisenberger, M. A., Khoury, S., Kozlowski, J. S., Kelly, K., Scher, H., and Hartley-Asp, B. Assessment of hormone refractory prostate cancer. Urology, 49 (Suppl. 4A): 46-53, 1997.
25. Sylvester, R. J., Denis, L., and de Voogt, H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. Eur. Urol., 33: 134-143, 1998.
26. Furaya, Y., Akimoto, S., Akakura, K., Igarashi, T., Murakami, S., Shimazaki, J., and Ito, H. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer. Urol. Int., 60: 28-32, 1998.
27. Schellhammer, P., Cockett, A., Boccon-Gibod, L., Gospodarowicz, M., Krongrad, A., Thompson, I. M., Scardino, P., Soloway, M., and Adolfsson, J. Assessment of endpoints for clinical trials for localized prostate cancer. Urology, 49 (Suppl. 4A): 27-38, 1997.